SCHEMBL5537849

SCHEMBL5537849

CCCCCCc1ccc2sc([O])nc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 5/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 1/20 0.43
STAT3 P40763 1/20 0.43
ATM Q13315 1/20 0.43
S1PR4 O95977 2/20 0.41
S1PR1 P21453 2/20 0.41
S1PR5 Q9H228 2/20 0.41
KAT8 Q9H7Z6 2/20 0.41
PPARA Q07869 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TNNC1 P63316 4/20 0.40
SGPL1 O95470 1/20 0.40
GPR183 P32249 1/20 0.40
CERS2 Q96G23 1/20 0.40
S1PR3 Q99500 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538752 0.94 HSD17B10 (0.43) NPC1RAB9ASMN1; SMN2MAPTATM
SCHEMBL5545673 0.88 CASP3 (0.47) TLR8NPC1RAB9ASMN1; SMN2S1PR4
SCHEMBL5541758 0.88 HSD17B10 (0.45) NPC1RAB9ASMN1; SMN2HSD17B10NFKB1
SCHEMBL5540542 0.87 CASP3 (0.48) TLR8NPC1RAB9ASMN1; SMN2
SCHEMBL9304665 0.84 TLR8 (0.45) TLR8NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL9306011 0.82 TLR8 (0.44) TLR8NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL5542728 0.82 CASP3 (0.52) NPC1RAB9ASMN1; SMN2MAPTATM
SCHEMBL5543821 0.81 NPC1 (0.47) NPC1RAB9ASMN1; SMN2MAPTHSD17B10
SCHEMBL10765715 0.78 PPARA (0.42) TLR8S1PR4S1PR1S1PR5KAT8
SCHEMBL2097222 0.77 TLR8 (0.40) TLR8NPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TLR8 1198/4885NPC1 2404/4885RAB9A 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.